Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers

Overview of attention for article published in Molecular Cancer Therapeutics, September 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter: 9 X users

patent: 1 patent

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 24 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

COMBINATION THERAPY

Application WO-2023039249-A1

World Intellectual Property Organisation (WIPO)